• Founded: 2018
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Parkinson's
  • Drug types: NEU, GEN, IMM
  • Lead product: NEU-723
  • Product link:
  • Funding: $100M C Mar 2022; $113M A/B Dec 2020

job board

Short description:

AI-drug discovery

Drug notes:

Undisclosed programs genetic neurological diseases, inflammatory & autoimmune diseases

Long description:

Neuron23 is a biotech company aiming to develop precision medicine for complex neurological and immunological diseases. They are leveraging recent advancements in human genetics to identify the underlying causes of diseases. Their state-of-the-art, AI-powered drug discovery platforms are used to design personalized therapies based on a patient's specific genetic makeup. Personalized medicine approaches can minimize side effects often experienced with broad-spectrum therapies. Neuron23 is also able to identify patients who will benefit most from their targeted treatments using their biomarker platforms. By targeting the root cause of the disease at the genetic level, Neuron23 is determined to develop more effective and potentially curative treatments.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy